WTIM
BMRN icon

Wilmington Trust Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wilmington Trust Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$236K Hold
3,800
– – 0.05% 316
2014
Q1 		$259K Buy
+3,800
New +$280K 0.05% 303

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Wilmington Trust Investment Management's BMRN Position: Q2 2014 in Review

Wilmington Trust Investment Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2014 at 3,800 shares worth $236K. The position accounts for 0.05% of the portfolio, ranked #316.

Wilmington Trust Investment Management first reported a position in BMRN in Q1 2014 and has held it in 2 quarters since. The position peaked at $259K in Q1 2014. 321 funds tracked by Wall St. Rank hold BMRN as of Q2 2014.

  • Wilmington Trust Investment Management held 3,800 shares of BioMarin Pharmaceuticals worth $236K as of Q2 2014.
  • Wilmington Trust Investment Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2014.
  • BioMarin Pharmaceuticals made up 0.05% of Wilmington Trust Investment Management's portfolio in Q2 2014, its #316 holding.
  • Wilmington Trust Investment Management first reported a position in BioMarin Pharmaceuticals in Q1 2014 and has held it in 2 quarters since.
  • Wilmington Trust Investment Management's BioMarin Pharmaceuticals position peaked at $259K in Q1 2014.
  • 321 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2014.

Based on Wilmington Trust Investment Management's 13F filing for Q2 2014, filed 13 Aug 2014.